Opdivo Qvantig

{"sequence":297,"product_key":"US:BLA:761381:001","judgment_status":"PROVISIONAL_EVIDENCE_SCREEN","review_basis":"LATER_RIGHT_SIGNAL","reason_codes":["LATER_PATENT_REFERENCE_DATE: US12582713","LATER_PARTIAL_SCOPE_ODE: 2027-03-10, 2027-06-10, 2027-10-02, 2028-04-16, 2028-05-20, 2029-05-27, 2030-02-15, 2030-10-13, 2032-04-11, 2033-03-20"],"unknown_patent_terms":[],"pending_publications":[],"regulatory_anchor":"2026-12-22","later_regulatory_events":[{"generic":"nivolumab","brand":"Opdivo","approval_date":"2021-04-16","approved_scope":"in combination with fluoropyrimidine- and platinum-containing chemotherapy for the treatment of patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma","protected_scope":"in combination with fluoropyrimidine- and platinum-containing chemotherapy for the treatment of patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma","source":"https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=545016","end_date_raw":"2028-04-16","end_date":"2028-04-16","date_display":"2028-04-16","record_relation":"RELATED_OR_COMBINATION_RECORD","whole_product_coverage":"N","adopted_as_whole_product_anchor":false},{"generic":"nivolumab","brand":"Opdivo","approval_date":"2021-05-20","approved_scope":"adjuvant treatment of completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease in patients who have received neoadjuvant chemoradiotherapy (CRT)","protected_scope":"adjuvant treatment of completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease in patients who have received neoadjuvant chemoradiotherapy (CRT)","source":"https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=545016","end_date_raw":"2028-05-20","end_date":"2028-05-20","date_display":"2028-05-20","record_relation":"RELATED_OR_COMBINATION_RECORD","whole_product_coverage":"N","adopted_as_whole_product_anchor":false},{"generic":"nivolumab","brand":"Opdivo","approval_date":"2020-06-10","approved_scope":"Opdivo (nivolumab) indicated for the treatment of patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy.","protected_scope":"For the treatment of patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy.","source":"https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=531016","end_date_raw":"2027-06-10","end_date":"2027-06-10","date_display":"2027-06-10","record_relation":"RELATED_OR_COMBINATION_RECORD","whole_product_coverage":"N","adopted_as_whole_product_anchor":false},{"generic":"nivolumab","brand":"Opdivo","approval_date":"2021-04-16","approved_scope":"in combination with fluoropyrimidine- and platinum-containing chemotherapy for the treatment of patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma","protected_scope":"in combination with fluoropyrimidine- and platinum-containing chemotherapy for the treatment of patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma","source":"https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=531016","end_date_raw":"2028-04-16","end_date":"2028-04-16","date_display":"2028-04-16","record_relation":"RELATED_OR_COMBINATION_RECORD","whole_product_coverage":"N","adopted_as_whole_product_anchor":false},{"generic":"nivolumab","brand":"Opdivo","approval_date":"2021-05-20","approved_scope":"adjuvant treatment of completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease in patients who have received neoadjuvant chemoradiotherapy (CRT)","protected_scope":"adjuvant treatment of completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease in patients who have received neoadjuvant chemoradiotherapy (CRT)","source":"https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=531016","end_date_raw":"2028-05-20","end_date":"2028-05-20","date_display":"2028-05-20","record_relation":"RELATED_OR_COMBINATION_RECORD","whole_product_coverage":"N","adopted_as_whole_product_anchor":false},{"generic":"nivolumab","brand":"Opdivo","approval_date":"2022-05-27","approved_scope":"In combination with ipilimumab, for the first-line treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC)","protected_scope":"in combination with ipilimumab, for the first-line treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC)","source":"https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=531016","end_date_raw":"2029-05-27","end_date":"2029-05-27","date_display":"2029-05-27","record_relation":"RELATED_OR_COMBINATION_RECORD","whole_product_coverage":"N","adopted_as_whole_product_anchor":false},{"generic":"nivolumab","brand":"Opdivo","approval_date":"2022-05-27","approved_scope":"In combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC)","protected_scope":"in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC)","source":"https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=531016","end_date_raw":"2029-05-27","end_date":"2029-05-27","date_display":"2029-05-27","record_relation":"RELATED_OR_COMBINATION_RECORD","whole_product_coverage":"N","adopted_as_whole_product_anchor":false},{"generic":"nivolumab and ipilimumab","brand":"OPDIVO and YERVOY","approval_date":"2020-10-02","approved_scope":"OPDIVO, in combination with ipilimumab, is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma.","protected_scope":"in combination with ipilimumab, for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma","source":"https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=595917","end_date_raw":"2027-10-02","end_date":"2027-10-02","date_display":"2027-10-02","record_relation":"RELATED_OR_COMBINATION_RECORD","whole_product_coverage":"N","adopted_as_whole_product_anchor":false},{"generic":"nivolumab and ipilimumab","brand":"OPDIVO and YERVOY","approval_date":"2020-10-02","approved_scope":"YERVOY (ipilimumab), in combination with nivolumab, is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma.","protected_scope":"In combination with nivolumab, for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma","source":"https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=595917","end_date_raw":"2027-10-02","end_date":"2027-10-02","date_display":"2027-10-02","record_relation":"RELATED_OR_COMBINATION_RECORD","whole_product_coverage":"N","adopted_as_whole_product_anchor":false},{"generic":"nivolumab","brand":"Opdivo","approval_date":"2023-02-15","approved_scope":"adjuvant treatment of adult and pediatric patients 12 years and older with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection","protected_scope":"adjuvant treatment of pediatric patients 12 years and older with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection","source":"https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=387612","end_date_raw":"2030-02-15","end_date":"2030-02-15","date_display":"2030-02-15","record_relation":"RELATED_OR_COMBINATION_RECORD","whole_product_coverage":"N","adopted_as_whole_product_anchor":false},{"generic":"nivolumab","brand":"Opdivo","approval_date":"2023-02-15","approved_scope":"As a single agent or in combination with ipilimumab, for the treatment of adult and pediatric patients 12 years and older with unresectable or metastatic melanoma","protected_scope":"as a single agent or in combination with ipilimumab, for the treatment of pediatric patients 12 years and older with unresectable or metastatic melanoma","source":"https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=387612","end_date_raw":"2030-02-15","end_date":"2030-02-15","date_display":"2030-02-15","record_relation":"RELATED_OR_COMBINATION_RECORD","whole_product_coverage":"N","adopted_as_whole_product_anchor":false},{"generic":"nivolumab","brand":"Opdivo","approval_date":"2023-10-13","approved_scope":"adjuvant treatment of adult and pediatric patients 12 years and older with completely resected Stage IIB, Stage IIC, Stage III, or Stage IV melanoma","protected_scope":"adjuvant treatment of adult and pediatric patients 12 years and older with completely resected Stage IIB or Stage IIC melanoma","source":"https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=387612","end_date_raw":"2030-10-13","end_date":"2030-10-13","date_display":"2030-10-13","record_relation":"RELATED_OR_COMBINATION_RECORD","whole_product_coverage":"N","adopted_as_whole_product_anchor":false},{"generic":"nivolumab","brand":"Opdivo","approval_date":"2026-03-20","approved_scope":"in combination with doxorubicin, vinblastine, and dacarbazine (AVD), for the treatment of adult and pediatric patients 12 years and older with previously untreated, Stage III or IV classical Hodgkin lymphoma (cHL)","protected_scope":"in combination with doxorubicin, vinblastine, and dacarbazine (AVD), for the treatment of adult and pediatric patients 12 years and older with previously untreated, Stage III or IV classical Hodgkin lymphoma (cHL)","source":"https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=442614","end_date_raw":"2033-03-20","end_date":"2033-03-20","date_display":"2033-03-20","record_relation":"RELATED_OR_COMBINATION_RECORD","whole_product_coverage":"N","adopted_as_whole_product_anchor":false},{"generic":"nivolumab","brand":"OPDIVO","approval_date":"2020-03-10","approved_scope":"OPDIVO, as a single agent or in combination with ipilimumab, is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.","protected_scope":"in combination with ipilimumab, for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib","source":"https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=489915","end_date_raw":"2027-03-10","end_date":"2027-03-10","date_display":"2027-03-10","record_relation":"RELATED_OR_COMBINATION_RECORD","whole_product_coverage":"N","adopted_as_whole_product_anchor":false},{"generic":"nivolumab","brand":"Opdivo","approval_date":"2025-04-11","approved_scope":"in combination with ipilimumab, for the first-line treatment of adult patients with unresectable or metastatic hepatocellular carcinoma (HCC)","protected_scope":"in combination with ipilimumab, for the first-line treatment of adult patients with unresectable or metastatic hepatocellular carcinoma (HCC)","source":"https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=489915","end_date_raw":"2032-04-11","end_date":"2032-04-11","date_display":"2032-04-11","record_relation":"RELATED_OR_COMBINATION_RECORD","whole_product_coverage":"N","adopted_as_whole_product_anchor":false}],"batch":"BLA-05-06","review_version":"1.1","selection_status":"DEEP_REVIEW","verified":false,"anchor_status":"OPERATIONAL_UNVERIFIED","rights_anchor_date":"2026-12-22","patent_anchor_numbers":[],"patent_term_verified":false,"canonical_judgment_confirmed":false,"first_biosimilar_approval_date":null,"first_final_generic_date":null,"has_existing_generic":null,"has_existing_biosimilar":null,"report":"BLA_05_06_50_JUDGMENT_20261021.html","report_sha256":"d3f5cba95e750a9f93f53184cc6d1c82c363bb5bb718ddbc60ccfe5c14efed29","regulatory_update_pending":true,"local_patent_review_pending":true,"FDA_followup":[{"issue":"FDA_RPE_DETERMINATION_AND_END_DATE_NOT_LOCATED","status":"UPDATE_PENDING","reason":"FDA PB target fields remain blank; no additional exact-target final determination located in the retrieved public FDA letters/review/administrative documents. Orange Book has no target BLA rows. Operational baseline retained with verified=false."}],"tail_patents":["US12582713"]}

Settlement launch rights generally apply only to the named parties and product scope. These records do not change GenericRadar patent/exclusivity anchors or current decisions.

No litigation or settlement record currently linked to this product.